G protein-coupled receptors

World Endometriosis Market Spotlight 2019-2026 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, June 19, 2019
Health, General Health, Hormones, Branches of biology, Endocrine system, Peptide hormones, Sex hormones, RTT, G protein-coupled receptors, Progonadotropins, Endometriosis, Gonadotropin-releasing hormone, Hormone receptor, Follicle-stimulating hormone

The "Market Spotlight: Endometriosis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Market Spotlight: Endometriosis" report has been added to ResearchAndMarkets.com's offering.
  • Endometriosis affects an estimated one in 10 women in the reproductive age group of 15-49 years.
  • The approved drugs in the endometriosis space target the gonadotropin-releasing hormone receptor, progesterone receptor, follicle-stimulating hormone, and androgen receptors.
  • Bayer leads industry sponsors with the highest number of clinical trials for endometriosis, followed by Takeda.

Prometic Presents New Data on PBI-4050 and its Mechanism of Action on Kidney Fibrosis at the 56th ERA/EDTA Congress

Retrieved on: 
Friday, June 14, 2019
G protein-coupled receptors, GPR84

An oral presentation will discuss the mechanism of action of PBI-4050 onto GPR40 and GPR84, two promising biological targets in the treatment of kidney fibrosis.

Key Points: 
  • An oral presentation will discuss the mechanism of action of PBI-4050 onto GPR40 and GPR84, two promising biological targets in the treatment of kidney fibrosis.
  • Three poster presentations will highlight the role of the two G protein-coupled receptors, GPR40 and GPR84, in various models of kidney injury and associated complications.
  • PBI-4050 is an orally active lead drug candidate with excellent safety and efficacy profiles confirmed in several in vivo experiments targeting fibrosis.
  • Prometic has active business operations in Canada, the United States, the Isle of Man and the United Kingdom.

Study Shows How Light Therapy Might Help Premature Babies Avoid Vision Problems

Retrieved on: 
Monday, April 1, 2019
Medicine, Neonatology, Clinical medicine, Branches of biology, G protein-coupled receptors, Vision, Circadian rhythm, Opsin, Preterm birth, Light therapy

The findings in Nature Cell Biology suggest it may be possible to use light therapy to help premature infants whose eyes are still developing avoid vision problems, according to researchers at Cincinnati Children's Hospital Medical Center .

Key Points: 
  • The findings in Nature Cell Biology suggest it may be possible to use light therapy to help premature infants whose eyes are still developing avoid vision problems, according to researchers at Cincinnati Children's Hospital Medical Center .
  • The process can be thrown out of balance in medically fragile premature babies.
  • The study is a collaboration of research institutions in the United States and Czech Republic led by Lang's team in Cincinnati.
  • To test the influence of light stimulation, the researchers used 380 nanometer violet colored light to activate signaling via opsin 5.

Okayama University Research: Inflammation in the Brain Enhances the Side-effects of Hypnotic Medication

Retrieved on: 
Wednesday, March 6, 2019
Branches of biology, Drugs, Neurochemistry, GABAA receptor positive allosteric modulators, Ion channels, Neurotransmitters, G protein-coupled receptors, Gába, Diazepam, gamma-Aminobutyric acid, GABA receptor, Receptor

BZDs act by activating a receptor in the brain known as the GABAA receptor (GABAR).

Key Points: 
  • BZDs act by activating a receptor in the brain known as the GABAA receptor (GABAR).
  • However, because drugs like BZDs can mimic these chemicals, they are used to stimulate the activity of GABAR in the lab.
  • The prolongation of reflex loss seen in mice given diazepam was thus linked directly to GABAR and inflammation in the brain.
  • GABA attaches to its receptor (GABAR) on the brain cells and induces inhibitory effects i.e., it decreases brain activity by calming it down.

Okayama University Research: Inflammation in the Brain Enhances the Side-effects of Hypnotic Medication

Retrieved on: 
Wednesday, March 6, 2019
Branches of biology, Drugs, Neurochemistry, GABAA receptor positive allosteric modulators, Ion channels, Neurotransmitters, G protein-coupled receptors, Gába, Diazepam, gamma-Aminobutyric acid, GABA receptor, Receptor

BZDs act by activating a receptor in the brain known as the GABAA receptor (GABAR).

Key Points: 
  • BZDs act by activating a receptor in the brain known as the GABAA receptor (GABAR).
  • However, because drugs like BZDs can mimic these chemicals, they are used to stimulate the activity of GABAR in the lab.
  • The prolongation of reflex loss seen in mice given diazepam was thus linked directly to GABAR and inflammation in the brain.
  • GABA attaches to its receptor (GABAR) on the brain cells and induces inhibitory effects i.e., it decreases brain activity by calming it down.

2019 Pipeline Insight: Cannabinoid Receptor Type 1 (CB1) Antagonist - ResearchAndMarkets.com

Retrieved on: 
Friday, February 22, 2019
Health, Pharmaceutical, Branches of biology, Cell biology, Cannabinoids, G protein-coupled receptors, Designer drugs, Cannabinoid receptor type 1, CB1, Cannabinoid, Receptor, Penicillium parvum, Rosonabant

The "Cannabinoid Receptor Type 1 (CB1) Antagonist - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cannabinoid Receptor Type 1 (CB1) Antagonist - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • Cannabinoid Receptor Type 1 (CB1) Antagonist - Pipeline Insight, 2019 offers comprehensive insights of the pipeline (under development) therapeutics scenario and growth prospects across Cannabinoid Receptor Type 1 (CB1) Antagonist development.
  • The report provides detailed coverage of the pipeline landscape for this mechanism of action, equipped with data from multiple sources with complete pipeline analysis by developmental stage, associated indications, route of administration and molecule type.
  • Offers detailed therapeutic product profiles of Cannabinoid Receptor Type 1 (CB1) Antagonist with key coverage of developmental activities including licensing & collaboration deals, patent details, designations, technologies, indications and chemical information
    Therapeutic assessment of the active pipeline products by stage, product type, molecule type, and route of administration
    Identify the product attributes and use it for target finding, drug repurposing, and precision medicine

Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study of Avexitide in Post-Bariatric Hypoglycemia (PBH) at Upcoming Endocrine Society (ENDO) Meeting 2019 in New Orleans

Retrieved on: 
Monday, February 4, 2019
Endocrine system, Organ systems, Endocrine diseases, Peptide hormones, Anti-diabetic drugs, Diabetes, G protein-coupled receptors, Glucagon-like peptide-1, Hyperinsulinemic hypoglycemia, Glucagon, Hypoglycemia, Reactive hypoglycemia

Avexitide is a first in class glucagon-like peptide-1 (GLP-1) antagonist in development for PBH as a convenient, novel liquid formulation for SC administration.

Key Points: 
  • Avexitide is a first in class glucagon-like peptide-1 (GLP-1) antagonist in development for PBH as a convenient, novel liquid formulation for SC administration.
  • Lee, C. et al; "28-Day Dosing with Avexitide Improves Hyperinsulinemic Hypoglycemia in Patients with Severe, Refractory Post-Bariatric Hypoglycemia: The PREVENT Study", Oral Presentation, OR20-5, March 25, 2019, Room 291, 12:00-12:15 PM CST.
  • Avexitide is a 31-amino acid peptide that selectively targets and blocks GLP-1 receptors, normalizing insulin secretion by the pancreas, and thereby reducing postprandial hypoglycemia.
  • Eiger does not assume any obligation to update any forward-looking statements, except as required by law.

GABA-Receptor Modulation in the Treatment of Neurological Diseases

Retrieved on: 
Tuesday, December 4, 2018
Neuroscience, Biology, Neurochemistry, Neurotransmitters, G protein-coupled receptors, Transmembrane receptors, Ion channels, Gába, gamma-Aminobutyric acid, GABA receptor, Inhibitory postsynaptic potential, GABAA receptor

Neurons transmit information in the brain and communicate with each other through surface molecules called receptors.

Key Points: 
  • Neurons transmit information in the brain and communicate with each other through surface molecules called receptors.
  • The main inhibitory receptor in the mammalian brain, GABA-A-receptors (GABAARs), are activated by the neurotransmitter GABA, which is released from neurons.
  • Thus, modulation of the signaling pathways that regulate s-GABARs activity may provide new and safer treatments for epilepsy.
  • Dr. Sylantyev said that "GABA-independent modulation of spontaneously opening GABA-receptors is a perspective direction for the search for new anti-epileptic drugs free from common side effects."